Regeneron, given to Trump, gets emergency US clearance for Covid-19 therapy

Trial findings released by Regeneron in October showed the drug may help treat patients outside the hospital.

Regeneron Pharmaceuticals Inc.’s antibody cocktail received an emergency use authorisation from U.S. drug regulators for treatment of early Covid-19 symptoms, adding to the expanding arsenal of therapies available to physicians.

The treatment, administered to President Donald Trump after he contracted the coronavirus in October, consists of two monoclonal antibodies that target the spike protein used by the virus to enter cells. Trump was treated with the drug based on a compassionate-use request by his doctors.

“In a clinical trial of patients with Covid-19, casirivimab and imdevimab, administered together, were shown to reduce Covid-19-related hospitalization or emergency room visits in patients at high